Akcea Therapeutics Inc (NASDAQ: AKCA) stock soars on positive prospects
Akcea Therapeutics Inc (NASDAQ: AKCA) TEGSEDI, got marketing authorization in the EU for treating stage 1 or stage 2 polyneuropathy in adult patients with hereditary…
Akcea Therapeutics Inc (NASDAQ: AKCA) TEGSEDI, got marketing authorization in the EU for treating stage 1 or stage 2 polyneuropathy in adult patients with hereditary…
Akcea Therapeutics Inc ( ) stock rose over 6.5% on April 20th, 2018 (as of 12:39 PM GMT-4; source: Google finance) as they got a…
Akcea Therapeutics Inc(NASDAQ: AKCA) stock rose over 32.7% on March 15th, 2018 (as of 12:41PM EDT; Source: Google finance) leading to a total rise of…